ICU Medical, Inc. (NASDAQ:ICUI) has been assigned an average broker rating score of 2.20 (Buy) from the five analysts that provide coverage for the company, Zacks Investment Research reports. Three equities research analysts have rated the stock with a hold rating and two have given a strong buy rating to the company.

Brokerages have set a 1 year consensus target price of $175.67 for the company and are forecasting that the company will post $0.73 EPS for the current quarter, according to Zacks. Zacks has also assigned ICU Medical an industry rank of 155 out of 265 based on the ratings given to related companies.

A number of research firms have commented on ICUI. Zacks Investment Research upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $193.00 price target on the stock in a research report on Thursday, July 20th. Gabelli reiterated a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. BidaskClub upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Finally, Sidoti lowered shares of ICU Medical from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 20th.

In related news, Chairman Vivek Jain sold 100,000 shares of ICU Medical stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $170.80, for a total transaction of $17,080,000.00. Following the transaction, the chairman now directly owns 110,925 shares of the company’s stock, valued at $18,945,990. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Robert S. Swinney sold 463 shares of ICU Medical stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $181.25, for a total value of $83,918.75. Following the transaction, the director now directly owns 14,330 shares in the company, valued at $2,597,312.50. The disclosure for this sale can be found here. Insiders sold a total of 213,012 shares of company stock worth $36,438,659 in the last three months. Company insiders own 15.90% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ICU Medical by 10.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 707 shares of the medical instruments supplier’s stock valued at $122,000 after purchasing an additional 66 shares in the last quarter. Riverhead Capital Management LLC grew its stake in shares of ICU Medical by 99.8% in the 2nd quarter. Riverhead Capital Management LLC now owns 999 shares of the medical instruments supplier’s stock worth $172,000 after purchasing an additional 499 shares during the last quarter. Victory Capital Management Inc. grew its stake in shares of ICU Medical by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 1,050 shares of the medical instruments supplier’s stock worth $181,000 after purchasing an additional 157 shares during the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of ICU Medical in the 1st quarter worth approximately $194,000. Finally, Parametrica Management Ltd acquired a new position in shares of ICU Medical in the 2nd quarter worth approximately $213,000. 78.13% of the stock is owned by institutional investors.

ICU Medical (NASDAQ ICUI) traded up 0.59% during mid-day trading on Thursday, reaching $189.10. The company’s stock had a trading volume of 59,335 shares. ICU Medical has a 52 week low of $125.49 and a 52 week high of $189.15. The firm’s 50 day moving average price is $177.38 and its 200 day moving average price is $166.78. The firm has a market capitalization of $3.75 billion, a P/E ratio of 75.73 and a beta of 0.35.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.06). The company had revenue of $331.51 million during the quarter, compared to analyst estimates of $318.30 million. ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The business’s revenue for the quarter was up 242.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.15 EPS. On average, analysts anticipate that ICU Medical will post $4.11 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/icu-medical-inc-icui-receives-consensus-rating-of-buy-from-analysts/1606272.html.

ICU Medical Company Profile

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.